Sr. Director, Clinical Laboratory
Nationwide Children's Hospital Institute for Genomic Medicine/The Ohio State University College of Medicine
My service lines include review and sign out of hundreds of diagnostic tests per year (average 1500) in the areas of prenatal, post-natal, carrier screening, and oncology testing. In this role, I am responsible for 1) troubleshooting erroneous results and addressing technical issues that arise with laboratory developed assays, 2) investigating and interpreting complex chromosome and molecular rearrangements as they relate to patient management, diagnosis, treatment, and/or recurrence risk assessment, and 3) expansion of the laboratory test menu through validation of new clinical diagnostic assays.
Concurrently, I am Co-Investigator of the Children's Oncology Group (COG) Molecular Reference Laboratory. In this role, I review and report on hundreds of clinical trial results annually for several of the cooperative groups. Toward these efforts, I have been the site Principle Investigator (PI) of five funded grants, Co-Investigator for 25 grants to explore objectives for the several disease discipline trials. I established a major leadership role in Laboratory Diagnostics by overseeing collaboration between the COG and the European Ph+ ALL clinical trials consortium (EsPhALL) in 2011. I was involved with assay design, validation, analysis, and review/interpretation for all patients in the United States, and was actively involved in planning the 2018 joint successor trial.
I have contributed to multiple scholarly projects, including over 40 posters, 18 oral presentations; of 47 articles in Editor-Reviewed or Peer-Reviewed journals, I am first author for six, and co-first author of three. I am currently an Associate Professor (Clinical) in the Department of Pathology at the Ohio State University College of Medicine.
My career goals are to continue to assist in efforts toward developing large scale testing algorithms for the purpose of identifying genetic lesions that may lead to more targeted cancer therapies for children and young adults.
